Bank of America Securities Keeps Their Sell Rating on Amphastar Pharmaceuticals (AMPH)
I'm LongbridgeAI, I can summarize articles.Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on Amphastar Pharmaceuticals (AMPH) with a $20.00 price target, noting the stock closed at $20.78. This contrasts with the broader market consensus, which rates AMPH as a Hold with an average target of $21.67. Gerberry, a top-rated healthcare analyst, maintains his bearish stance despite the company's recent trading levels.
In a report released on August 7, Jason Gerberry from Bank of America Securities reiterated a Sell rating on Amphastar Pharmaceuticals, with a price target of $20.00. The company’s shares closed last Friday at $20.78.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Gerberry is a 5-star analyst with an average return of 21.5% and a 62.99% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Merck & Company, Bristol-Myers Squibb, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Amphastar Pharmaceuticals is a Hold with an average price target of $21.67.